ライフサイエンスコーパス: bile duct cancer

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ive assessment of the proximal versus distal bile duct cancer.

2 lliation and survival in nonresectable hilar bile duct cancer.

3 for gallbladder cancer, 97% of extrahepatic bile duct cancer, 91% of ampula of Vater cancer, 96% of

4 able for both toxicity and response: 11 with bile duct cancer and four with gall-bladder carcinoma.

5 m of the secretin receptor in pancreatic and bile duct cancers and developed a dual antibody sandwich

6 ampula of Vater cancer, 96% of intrahepatic bile duct cancer, and 94% of hepatocellular carcinoma.

7 ) arose in the ampulla, 30 (12%) were distal bile duct cancers, and 17 (7%) were duodenal cancers.

8 g a risk factor for developing an aggressive bile duct cancer, cholangiocarcinoma, in chronically inf

9 tionship to the pathogenesis of human distal bile duct cancer (DBDC).

10 A consecutive cohort of patients with bile duct cancer (hilar, intrahepatic, or distal) was re

11 the development of sclerosing cholangitis or bile duct cancers in XHIM patients.

12 colorectal, liver, pancreas, and gallbladder/bile duct cancers) in 69,310 nonsmoking and non-alcohol-

13 mation, a risk factor for the development of bile duct cancer, induces inducible nitric oxide synthas

14 The incidence of bile duct cancer is low but increasing.

15 mpullary cancer (n = 70; 11%), distal common bile duct cancer (n = 65; 10%), duodenal cancer (n = 26;

16 tail of pancreas, cancer of the extrahepatic bile duct, cancer of the gallbladder, and cancer of the

17 We studied 564 consecutive patients with bile duct cancer operated upon between 1973 and 2004.

18 (P < .001) and gallbladder and extrahepatic bile duct cancer (P = .01) was observed.

19 rs1126580), was associated with the risk of bile duct cancer (P = 0.003) and biliary stones (P = 0.0

20 oporfin-PDT can safely be delivered to hilar bile duct cancer patients and results in prolonged paten

21 for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positi

22 en hepatocellular carcinoma risk factors and bile duct cancer remains to be clarified.

23 IPNBs are an uncommon variant of bile duct cancer, representing approximately 10% of all

24 range 47-88] years) with nonresectable hilar bile duct cancer were treated with T-PDT (median 1 [rang

25 hepatic cholangiocarcinoma (iCCA) is a fatal bile duct cancer with dismal prognosis and limited thera

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。